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(http://creativecommoheimer’s disease to evaluate the safety and dose-limiting toxicity of stereotactic brain injection of hu-
man umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs).
Methods: The low- (n5 3) and high-dose (n5 6) groups received a total of 3.0! 106 cells/60 mL
and 6.0! 106 cells/60 mL, respectively, into the bilateral hippocampi and right precuneus.
Results: No patient showed serious adverse events including fever during the 24-month follow-up
period. During the 12-week follow-up period, the most common acute adverse event was wound
pain from the surgical procedure (n5 9), followed by headache (n5 4), dizziness (n5 3), and post-
operative delirium (n 5 3). There was no dose-limiting toxicity.
Discussion: Administration of hUCB-MSCs into the hippocampus and precuneus by stereotactic in-
jection was feasible, safe, and well tolerated. Further trials are warranted to test the efficacy.
Clinical Trial Registration: ClinicalTrial.gov identifier NCT01297218 and NCT01696591.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Alzheimer’s disease (AD) dementia is a neurodegenera-
tive disease that results in progressive dementia. Currently,
no approved disease-modifying treatments are available
for AD. Mesenchymal stem cells (MSCs) are multipotent
stem cells that are capable of self-renewal and differentiation
into various cell types when cultured under appropriateeimer’s Association. This is an open access article under the CC BY license
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likely to differentiate into neurons when injected into the
brain. Rather, MSCs secrete various cytotropic factors that
may exert beneficial effects in AD mice through various
mechanisms such as reducing amyloid burden, decreasing
inflammation,or increasing endogenous neurogenesis [2–
4]. Several human clinical trials have suggested that MSCs
are effective in slowing down the course of
neurodegenerative diseases such as Parkinson’s disease
[5], multiple system atrophy [6], and amyotrophic lateral
sclerosis [7,8]. However, to the best of our knowledge,
there has been no clinical trial that has attempted to treat
human AD using MSCs.
Given the lack of an effective regimen for AD dementia,
more innovative treatments are needed to effectively alter
the course of the disease. There has been little evidence
regarding the ability of MSCs, injected either intraarterially
or intravenously, to penetrate through the blood-brain bar-
rier for engraftment into the brain parenchyma of AD de-
mentia patients. Thus, to test the therapeutic potentials of
MSCs, we directly transplanted MSCs into the brains of
human AD patients using stereotactic surgery because the
most effective route of delivering MSCs into a targeted
structure may be through direct implantation. Indeed, a
recent phase 1 clinical trial reported that the stereotactic in-
jection of nerve grow factor into the nucleus basalis of
Meynert of AD dementia patients is both feasible and
well tolerated [9].
In the present study,we targeted the hippocampus and pre-
cuneus as injection sites because they are areas that are pre-
dominantly affected during the earlier phases of AD
dementia. According to pathologic and imaging studies, the
precuneus is where amyloid start to accumulate in the course
of AD [10,11] and the hippocampus is where neurofibrillary
tangles begin to aggregate during the progression ofAD [12].
Consistent with these data, recent functional neuroimaging
studies have suggested a central role of the precuneus in
memory [13] and that decreased hippocampus-precuneus
functional connectivity is an early sign of AD [14]. Further-
more, the hippocampus and precuneus undergo atrophy in the
early stages of AD dementia [15].
MSCs can be isolated from the umbilical cord blood,
which have been widely used in various clinical settings
[16–18]. Establishing the safety and feasibility of a
surgical method to effectively deliver human umbilical
cord blood–derived MSCs (hUCB-MSCs) into the
hippocampus and precuneus would represent an important
milestone in advancing the application of this novel
treatment for AD dementia. Therefore, the aim of this
study was to evaluate the safety and tolerability of surgical
stereotactic injection of hUCB-MSCs into the bilateral hip-
pocampus and right precuneus and to assess the maximum
tolerated dose. We also investigated the potential efficacy
of hUCB-MSCs in AD patients using cognitive measure-
ments and imaging markers.2. Methods
2.1. Study design
This was an open-label, single-center, phase 1 clinical
trial performed at Samsung Medical Center. The first three
AD dementia patients received a low dose (a total of
3.0! 106 cells, 1.0! 106 in each side of the hippocampus
and 1.0! 106 in the right precuneus) of hUCB-MSCs. After
we confirmed that there were no serious adverse events,
additional six AD dementia patients were selected to receive
a high dose (a total of 6.0! 106 cells, 2.0! 106 in each side
of the hippocampus and 2.0! 106 in the right precuneus) of
hUCB-MSCs via the same route. We injected MSCs into
only the right precuneus to compare the change in amyloid
burden level in the MSC-treated right precuneus with that
in the untreated left precuneus. This trial was registered at
ClinicalTrial.gov (ClinicalTrial.gov number NCT01297218
for 12 weeks of follow-up; NCT01696591 for extended
follow-up of 24 months). We obtained written informed con-
sent from every patient or their legally authorized represen-
tatives in cases of impaired capacity. This study was
approved by the Institutional Review Board of Samsung
Medical vCenter.2.2. Participants
Eligible patients were aged 50–75 years, fulfilled the
criteria for probable AD dementia according to the National
Institute of Neurological and Communicative Disorders
Stroke and AD and Related disorders Association [19],
and had a mini-mental state examination (MMSE) score bet-
ween 10 and 24. Patients with neurologic diseases other than
AD dementia were excluded, as were those with one or more
of the following conditions: severe white matter hyperinten-
sities on fluid-attenuated inversion recovery (FLAIR) im-
ages at baseline, which were defined as a cap or band
(periventricular white matter hyperintensities) 10 mm,
and deep white matter lesions (deep white matter hyperin-
tensities) 25 mm as modified from the Fazekas ischemia
criteria [20]; major psychiatric disorder; history of stroke
within 3 months of enrollment; hepatic, renal, hematologic,
or active pulmonary disorder; history of alcohol abuse; and/
or underlying malignancy. Patients were required to have
been on a stable dose of acetylcholinesterase inhibitors or
memantine for at least 60 days before enrollment, and the
same dose of medication was continued throughout the
study. Nine patients who met the mentioned criteria were
also evaluated for amyloid burden using 11C-labeled Pitts-
burgh compound B (PiB) positron emission
tomography (PET) as well as the downstream neuronal
degeneration biomarker using [18F]fluoro-2-deoxy-
D-glucose (FDG) PET and structural brain magnetic reso-
nance imaging (MRI). All nine patients were positive for
amyloid (standardized uptake value ratio [SUVR] 1.5),
had decreased FDG uptake in the temporoparietal cortex,
Table 1
Baseline characteristics of participants
Subject Age Gender Education, y Medication MMSE ADAS-Cog PiB SUVR
LD01 59 Male 10 AChE-I 23 18 2.7
LD02 58 Male 18 AChE-I and memantine 12 51 2.17
LD03 54 Male 6 AChE-I and memantine 10 47 2.27
HD01 74 Male 16 AChE-I and memantine 18 36 2.53
HD02 62 Male 18 AChE-I 17 30 1.51
HD03 74 Male 12 AChE-I 20 21 2.27
HD04 58 Female 16 AChE-I 12 37 2.51
HD05 60 Female 9 AChE-I and memantine 18 29 2.17
HD06 56 Female 12 AChE-I 20 15 2.28
Abbreviations: MMSE, mini-mental state examination; ADAS-Cog, Alzheimer’s disease assessment scale-cognitive subscale; PiB SUVR, Pittsburgh
compound B standardized uptake value ratio; LD, low dose; AChE-I, acetylcholine esterase inhibitor; HD, high dose.
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temporal lobe, and parietal cortex. Therefore, all the enrolled
patients satisfied the research criteria for high likelihood of
ADwith biomarker evidence for amyloid and neurodegener-
ation as proposed by the National Institute on Aging-Alz-
heimer’s Association workgroup [21].
The baseline characteristics of each individual subject are
listed in Table 1. The mean age was 57.0 years in the low-
dose group and 64.0 years in the high-dose group.2.3. Preparation of hUCB-MSCs
To be used for clinical purposes, hUCB-MSCs were man-
ufactured in compliance with Korea Good Manufacturing
Practices (KGCP) standards. Cell quality control and quality
assurance were performed in compliance with KGCP stan-
dards. hUCB tissue was obtained after receiving written
informed consent from normal women in their full-term preg-
nancy. hUCB-MSCswere grown in a-minimum essential me-
dium (a-MEM; Gibco/Life Technologies, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (Gibco/
Life Technologies). Cells were cryopreserved at 2150C or
lower using 10% dimethyl sulfoxide.
To prepare for surgical injection, frozen hUCB-MSCs
were first thawed, seeded, and cultured. The cells were har-
vested 5 days after seeding, repeatedly washed to remove
impurities such as fetal bovine serum and trypsin, and resus-
pended in an appropriate amount of phenol red-free a-MEM.
Therefore, fetal bovine serum is not present in the final drug
product, NEUROSTEM. hUCB-MSCs were tested for
viability, phenotype, and presence of endotoxins, bacteria,
and mycoplasma. After testing, 50 million cells were resus-
pended in 1 mL of phenol red-free a-MEM and of the 1 mL,
60 mL was used to inject to each patient in the low-dose
group. For the high-dose group, from the adjusted final con-
centration of 100 million cells per 1 mL of phenol red-free
MEM-a, an equivalent volume of 60 mL was prepared for
administration into each individual patient in the high-dose
group. These samples were then delivered to the patient’s
physician. hUCB-MSCs were stored at 2–8C and had a
shelf life of about 44 hours from the time of manufacture.Using flow cytometric analyses, the expressions of surface
antigens of the cells were consistently positive for CD73,
CD90, CD105, and CD166 but negative for CD45, CD14,
and HLA-DR.2.4. Stereotactic administration of hUCB-MSCs
Patients underwent perioperative stereotaxic MRI to
localize the left and right hippocampi as well as the right
precuneus. Intraoperative navigation–guided stereotactic
injection was performed by the same surgeon under gen-
eral anesthesia. Frameless stereotaxis and the BrainLab
system were used to inject hUCB-MSCs to the target
point. We used a custom-made guiding cannula with a
1.3-mm outer diameter and a 1.1-mm inner diameter.
The cannula had a blunt stylet within the lumen to avoid
coring when being passed through the parenchyma. The
guiding cannula was deigned to expose the distal
10 mm of a Hamilton syringe needle. When the cannula
tip reached the target, the stylet was taken out and the
absence of bleeding or cerebrospinal fluid (CSF) leak
was confirmed. Then the cannula was retracted 10 mm,
and then a Hamilton syringe (model 702) with a 22-
gauge needle was inserted through the cannula. After
reaching the cannula tip, the needle was further advanced
10 mm to reach the target point. We manually injected
hUCB-MSCs at approximately 5 mL/5 min at each site.
The injection needle was left in place for 5 minutes and
then slowly retracted 5 mm for the next site injection.
For hippocampal injection, the cannula was inserted
through burr holes on each side parallel to the temporal
horn border of the lateral ventricle to the mid portion of
the hippocampal body, in which the tip was placed 5-mm
posterior to the border of lateral ventricle (Fig. 1C). As illus-
trated in Fig. 1A, each trajectory (left and right hippocampi
and right precuneus) consisted of four injection sites. That is,
hUCB-MSCs (2.5! 105 cells/5 mL per site for the low dose
and 5.0! 105 cells/5 mL per site for the high dose) were in-
jected at four sites (5-mm intervals) along the inserted trajec-
tory for both the left and right hippocampi. For precuneus
injection, the cannula was inserted perpendicular to the skull
Fig. 1. Intraoperative navigation–guided stereotactic administration of hUCB-MSCs. hUCB-MSCs were injected into the right and left hippocampus and right
precuneus at four sites (5-mm intervals) along the inserted trajectory while retracting the cannula (A). However, in six of nine patients, the fourth injection was
located on the temporal horn of the lateral ventricle, probably due to substantial hippocampal atrophy. In these cases, the omitted doses were injected into the
right precuneus, resulting in three injection sites in each hippocampus and six sites in the right precuneus (B). An example of stereotactic administration of
hUCB-MSCs into the left hippocampus (C). Each patient received 12 injections for a total of 3.0 ! 106 cells/60 mL in the low dose group or
6.0! 106 cells/60 mL in the high dose group. Abbreviation: hUCB-MSCs, human umbilical cord blood–derived mesenchymal stem cells.
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site for the low dose and 5.0! 105 cells/5 mL per site for the
high dose) were injected at four sites (5-mm intervals) along
the inserted trajectory for the right precuneus (Fig. 1A).
Thus, each patient was injected with a total of 3.0! 106 cells
suspended in 60 mL for the low-dose condition or
6.0 ! 106 cells in 60 mL for the high-dose condition. For
the hippocampal injections, hUCB-MSCs were implanted
into the four designated sites as the cannula was retracted.
However, in six of nine patients, the fourth injection was
located on the temporal horn of the lateral ventricle, which
was not possible to inject, likely due to substantial hippo-campal atrophy. In these cases, we omitted the fourth dose,
only injecting in to a total of three sites for each hippocam-
pus, and instead injected the omitted doses into the right pre-
cuneus resulting in a total of six sites as illustrated in Fig. 1B.
Although injecting the missed hippocampal dose into the
precuneus would lead to a potential bias when comparing
the efficacy between low-dose and high-dose groups, this
method was necessary to reduce bias in terms of assessing
safety and dose-limiting toxicity, which was our primary
goal. Participants were hospitalized for 4–6 days after surgi-
cal injection and were observed for signs of acute adverse
events.
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Our primary goal was to assess the safety and dose-
limiting toxicity of two ascending doses of hUCB-MSCs.
Patients were assessed at baseline; 1, 2, 4, 7, and 14 days;
4, 8, and 12 weeks; and 12, 18, and 24 months after
hUCB-MSC injection. Safety was evaluated by examining
vital signs, weight, physical and neurologic examinations,
chest x-rays, and clinical laboratory testing (hematologic
and serum chemical testing, and urinalysis). Adverse events
were assessed at each visit. Acrovan Co, Ltd (Anyang,
Korea) served as an external monitor of the study.
To detect immunologic reactions between the implanted
hUCB-MSCs and the recipient, a mixed lymphocyte reac-
tion was assessed at baseline and at 12 weeks and 12 months
after injection. To detect structural abnormalities including
brain tumor or hemorrhage, patients underwent brain
computed tomography (CT) 24 hours after surgical injection
and brain MRI at 12 weeks and 24 months after injection.Table 2
Adverse events that were observed in at least one subject during the 12-wk
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0 (0.0) 4 (66.7) 4 (44.4)2.6. Clinical and laboratory assessments
To measure clinical changes, patients underwent AD
assessment scale-cognitive subscale (ADAS-Cog) testing,
Seoul instrumental activities of daily living (S-IADL),
MMSE, and caregiver-administered neuropsychiatric inven-
tory at baseline and again at 4 weeks, 12 weeks, and
24 months after hUCB-MSC injection.
To measure changes in parenchymal amyloid deposition,
patients underwent PiB-PET at baseline and again at 4 and
12 weeks after hUCB-MSC injection, and changes in
SUVR were assessed. To measure metabolic changes, pa-
tients underwent FDG-PETat baseline and at 12 weeks after
hUCB-MSC injection. To evaluate changes in CSF bio-
markers, CSF amyloid-b, total-tau, and phosphorylated-tau
were evaluated at baseline, 4, and 12 weeks after hUCB-
MSC injection. CSF was collected in a sterile polypropylene
tube with a conical bottom through lumbar puncture at L3–
L5 level using a 22-gauge needle, as recommended by Alz-
heimer’s Biomarkers Standardization Initiative [22]. Details
of the imaging procedures for PiB-PET and FDG-PET are
provided in the Supplementary Material, available online.Nausea 0 (0.0) 2 (33.3) 2 (22.2)
Colonic polyp 0 (0.0) 1 (16.7) 1 (11.1)
Vomiting 0 (0.0) 1 (16.7) 1 (11.1)
Procedural
complications, n (%)
3 (100.0) 6 (100.0) 9 (100.0)
Wound pain 3 (100.0) 6 (100.0) 9 (100.0)
Ligament sprain 0 (0.0) 1 (16.7) 1 (11.1)
Nervous system
disorders, n (%)
1 (33.3) 4 (66.7) 5 (55.6)
Headache 1 (33.3) 3 (50.0) 4 (44.4)2.7. Statistical analysis
Because of the small number of participants, absence of
sham surgery control, and the fact that it was an open-
labeled study design, we did not perform statistical analysis
to compare the outcome measures of the low- and high-dose
hUCB-MSC recipients.Dizziness 0 (0.0) 3 (50.0) 3 (33.3)
Psychiatric
disorders, n (%)
0 (0.0) 3 (50.0) 3 (33.3)
Delirium 0 (0.0) 3 (50.0) 3 (33.3)
Others, n (%) 1 (33.3) 1 (16.7) 2 (22.2)
Back pain 1 (33.3) 1 (16.7) 2 (22.2)
Asthenia 1 (33.3) 0 (0.0) 1 (11.1)3. Results
3.1. Compliance and safety
All the enrolled patients completed the 12-week follow-up
trial; however, during the 24-month extended follow-up study,one patient was excluded due to revocation of consent. hUCB-
MSCs injected through the stereotaxicmethodwas completed
safely in all nine subjects. Brain CT scans taken within
24 hours after injection confirmed that there was no cerebral
hemorrhage in any of the patients. Vital signs and weights
were stable, and there was no incidence of fever in any of
the patients. Likewise, there were no treatment-related alter-
ations in hematologic parameters. The most common acute
adverse event (during the 12-week follow-up) was wound
pain from the surgical procedure 9/9 (100%), followed by
headache 4/9 (44.4%), dizziness 3/9 (33.3%), delirium 3/9
(33.3%), nausea 2/9 (22.2%), and back pain 2/9 (22.2%;
Table 2); however, none of these adverse events were consid-
ered serious. Therewas no adverse event during the 24-month
extended follow-up study. Furthermore, all the noticeable
adverse events were deemed by investigators as unlikely to
be stemcell–related adverse events andwere instead attributed
to surgery-related adverse events. Three patients developed
mild delirium that lasted between 24 hours and 5 days, which
was assumed to be postoperative delirium.
BrainMRIs taken 12 weeks and 24months after the injec-
tions confirmed that there were no structural abnormalities
including tumor and subdural hemorrhages. Furthermore,
no dose-limiting toxicities were evident for either the low-
or high-dose hUCB-MSC groups. Results of the mixed
lymphocyte reaction performed at 12 weeks and 12 months
after injection showed that all nine subjects were immuno-
logically stable.
3.2. Clinical and laboratory outcome measures
The changes in ADAS-Cog score from baseline to week
12 and month 24 in the low-dose group were 5.3 6 3.5
H.J. Kim et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 95-102100and 20.0 6 9.9 points, respectively, whereas those in the
high-dose group were 3.5 6 5.6 and 8.6 6 13.1 points,
respectively (Table 3). The changes in S-IADL score from
baseline to week 12 and month 24 were 1.7 6 4.0 and
19.5 6 6.4 points for the low-dose group and 1.2 6 5.9
and 12.0 6 6.0 points for the high-dose group, respectively
(Table 3). In addition, the changes in MMSE score from
baseline to week 12 and month 24 were 21.7 6 0.6 and
29.5 6 0.7 points for the low-dose group and 0.5 6 2.1
and28.46 5.6 points for the high-dose group, respectively
(Table 3).
Changes in the incidence of neuropsychiatric symptoms
are shown in Supplementary Table 1. Biomarker changes
such as amyloid burden measured by PiB-PET, glucose
metabolism measured by FDG-PET, and CSF biomarker
level are demonstrated in Supplementary Fig. 1. Although
our small sample size precluded statistical analysis, amyloid
burden levels in the hUCB-MSC–treated right precuneus did
not differ from those of the untreated left precuneus
(Supplementary Fig. 1).4. Discussion
This phase 1 clinical trial demonstrated that surgical
stereotactic administration of a low (3.0 ! 106 cells/
60 mL) or high dose (6.0 ! 106 cells/60 mL) of hUCB-
MSCs into the hippocampus and precuneus is feasible,Table 3
Changes in ADAS-Cog, S-IADL, and MMSE scores before and after the hUCB-M
ADAS-Cog S-IADL
Low dose High dose Total Low dose
Screening
Mean 6 SD 38.7 6 18 28.0 6 8.6 31.6 6 12.5 22.0 6 12.3
Median 47 29.5 30 17
Min to max 18 to 51 15 to 37 15 to 51 13 to 36
Week 4
Mean 6 SD 38.7 6 17.4 30.5 6 8.3 33.2 6 11.6 24.0 6 13.5
Median 45 29 29 20
Min to max 19 to 52 21 to 45 19 to 52 13 to 39
Week 12
Mean 6 SD 44.0 6 18.2 31.5 6 10.9 35.7 6 14 23.7 6 11.7
Median 53 32.5 33 19
Min to max 23 to 56 14 to 43 14 to 56 15 to 37
Month 24
Mean 6 SD 54.5 6 13.4 39.2 6 10.8 43.6 6 12.8 34.5 6 3.5
Median 54.5 46 46 34.5
Min to max 45 to 64 23 to 48 23 to 64 32 to 37
Mean change from baseline to week 12
Mean 6 SD 5.3 6 3.5 3.5 6 5.6 4.1 6 4.8 1.7 6 4.0
Median 5.0 3.5 4.0 1.0
Min to max 2 to 9 23 to 13 23 to 13 22 to 6
Mean change from baseline to month 24
Mean 6 SD 20.0 6 9.9 8.6 6 13.1 11.9 6 12.7 19.5 6 6.4
Median 20 12 13 19.5
Min to max 13 to 27 214 to 18 214 to 27 15 to 24
Abbreviations: ADAS-Cog, Alzheimer’s disease assessment scale-cognitive sub
mental state examination; hUCB-MSC, human umbilical cord blood–derived messafe, and well tolerated in patients with mild-to-
moderate AD dementia.
Our study is the first, reported so far, to demonstrate the
safety of hUCB-MSC injections into the hippocampus and
precuneus by stereotactic surgery. We were especially con-
cerned about whether the patients might experience fever,
as this has been a frequently reported adverse event in
MSC clinical trials [23]. However, none of the nine patients
experienced fever. Although some patients experienced
wound pain, headache, dizziness, and delirium, there were
no reports of serious adverse events related to stem cell treat-
ment. Indeed, a meta-analysis of MSC clinical trials showed
that MSC therapy does not increase risk of acute infusional
toxicity, arrhythmia, cardiac dysfunction, gastrointestinal or
renal dysfunction, infection, death, or tumor development
[23]. Thus, the surgical procedure involving the hippocam-
pal and precuneus injections of hUCB-MSCs can be consid-
ered safe. The results of this present study may pave a new
road for future AD studies.
There were no trends with respect to changes in the AD
pathophysiological process as measured by PiB-PET. We ex-
pected to see a decrease of PiB SUVR values at the sites in-
jected with hUCB-MSCs, as in vitro and in vivo animal
studies have consistently shown the neuroprotective effects
of hUCB-MSCs against amyloid. Indeed, a study showed
that hUCB-MSCs protect against Aß42-induced cell death
by secreting galectin-3 [3]. Likewise, another study reportedSC injection
MMSE
High dose Total Low dose High dose Total
22.8 6 7.9 22.6 6 8.8 15.0 6 7.0 17.5 6 2.9 16.7 6 4.4
21 19 12 18 18
12 to 32 12 to 36 10 to 23 12 to 20 10 to 23
23.2 6 5.8 23.4 6 8.1 15.7 6 5.7 16.0 6 4.0 15.9 6 4.3
24.5 24 14 16.5 16
12 to 28 12 to 39 11 to 22 9 to 21 9 to 22
24.0 6 7.9 23.9 6 8.6 13.3 6 6.7 18.0 6 4.1 16.4 6 5.2
24.5 24 10 18 18
14 to 34 14 to 37 9 to 21 11 to 24 9 to 24
37.0 6 6.7 36.3 6 6.0 8.0 6 7.1 8.6 6 7.6 8.4 6 6.9
41 37 8 12 12
29 to 44 29 to 44 3 to 13 0 to 17 0 to 17
1.2 6 5.9 1.3 6 5.1 21.7 6 0.6 0.5 6 2.1 20.2 6 2.0
2.0 2.0 22.0 0.5 21.0
28 to 8 28 to 8 22 to 21 22 to 4 22 to 4
12.0 6 6.0 14.1 6 6.7 29.5 6 0.7 28.4 6 5.6 28.7 6 4.7
11 12 29.5 26 29
6 to 22 6 to 24 210 to 9 217 to 3 217 to 3
scale; S-IADL, Seoul instrumental activities of daily living; MMSE, mini-
enchymal stem cell; SD, standard deviation.
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of AD mice decreases the formation of Aß42 plaques in the
hippocampus and other regions, which is associated with
the migration of hUCB-MSCs toward Aß deposits [2]. How-
ever, our single injection of hUCB-MSCs into the human
brain did not replicate findings from the animal studies. The
discrepancy between animal experiments and our human trial
may be explained by several possibilities. First, PiB-PETmay
not be sufficiently sensitive to detect soluble amyloid or
diffuse amyloid plaques [24]. Reduction of amyloid burden
after MSC administration in mice was detected through
biochemical analysis including immunohistochemical stain-
ing, enzyme-linked immunosorbent assay, and Western blot,
which can detect soluble and insoluble amyloid as well as
different types of amyloid plaques, whereas in our study,
changes in amyloid were measured by PiB-PET, which may
only detect neuritic amyloid plaques [24]. Second, differences
in ADmicroenvironment between humans andmousemodels
may explain the different responses to hUCB-MSCs. For
example, the APP-PS1 mice used in our previous animal ex-
periments show amyloid accumulation without neuronal loss
or inflammation in the brain, whereas humans show both am-
yloid and tau pathologies with consequent neuronal loss and
inflammation. Moreover, prior autopsy studies indicated that
more than 50% of clinically diagnosed AD patients harbor
other mixed pathologies in addition to amyloid plaques and
tau tangles [25,26]. Therefore, different pathologic
environments of the brain may explain the different
responses to MSC treatment. As a third possible
explanation, mouse AD models rely on xenogeneic
transplantation, whereas human trials involved allogeneic
transplantation. Thus, with respect to phylogeny, it is
possible that lower-order species may benefit more when
given MSCs from higher-order species than vice versa.
Finally, the absence of an effect may have been due to the
fact that the sample size was too small to demonstrate statis-
tical significance.
With respect to treatment efficacy, the lack of controls
and small sample size preclude any conclusion. However,
the rate of cognitive decline (nine-point drop in MMSE
within 2 years) was faster than typical AD (three-point
drop inMMSE per year) [27].We assume that this is because
seven of nine participants were early onset AD, which is
known to progress faster than typical late-onset AD [28].
Indeed, different rates of progression have been reported
among patients with aggressive form of AD showing a
decrease in MMSE score six points per year [29,30].
This study has several limitations. First, because this
study had an open-label design with no sham surgery control
group and a small number of participants, we could not
confirm the efficacy. Second, although we used a stereotaxic
injection method, the possibility of hUCB-MSCs being in-
jected into the CSF or subdural space cannot be excluded.
However, the error of intraoperative navigation is reported
to be up to 2 mm, and we confirmed that the cannula tip
was not placed in CSF or blood vessel by verifying noCSF or blood leak through the cannula. Third, passing the
needle longitudinally through the hippocampus or precuneus
might cause iatrogenic damage. However, to minimize such
damage, we used a cannula that had a blunt stylet within the
lumen to avoid coring when being passed through the paren-
chyma.5. Conclusions
We conclude that stereotactic administration of hUCB-
MSCs into the hippocampus and precuneus is feasible,
safe, and well tolerated. We believe that our study paves
the way for additional cell therapy studies. The remaining
challenge is to determine if hUCB-MSC injections pro-
vide clinical benefit by either slowing or even revising
the progression of AD symptoms. Further clinical trials
with placebo controls, larger sample size, and a long-
term follow-up period are warranted to test the efficacy
of this treatment. In addition, new and effective protocols
should be developed to augment the MSC effects on AD
pathology and to allow repeated injections of hUCB-
MSCs because the survival time of hUCB-MSCs injected
in the mouse brain is reported to be approximately 4
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1. Systematic review: The authors reviewed the liter-
ature using traditional (e.g., PubMed) sources and
meeting abstracts and presentations. Preclinical
studies suggest that human umbilical cord
blood–derived mesenchymal stem cells (hUCB-
MSCs) are beneficial in Alzheimer’s disease
(AD) mice. Several human clinical trials have sug-
gested that MSCs are effective in slowing down
the course of neurodegenerative diseases such as
Parkinson’s disease, multiple system atrophy,
and amyotrophic lateral sclerosis. However, to
the best of our knowledge, there has been no
H.J. Kim et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 95-102102clinical trial that has attempted to treat human AD
by using MSCs.
2. Interpretation: This phase 1 clinical trial suggests
that administration of hUCB-MSCs into the hippo-
campus and precuneus by stereotactic injection is
feasible, safe, and well tolerated.
3. Future directions: Further clinical trials with placebo
controls, larger sample size, and a long-term follow-
up period are warranted to test the efficacy of this
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